Looking to highlight a funding opportunity? Please send a brief description, link, and deadline to email@example.com
State & Federal Programs
The National Cancer Institute (NCI) announces the availability of a funding opportunity aimed at accelerating the development and commercialization of highly innovative technologies that improve molecular and/or cellular analysis of cancer with a significant likelihood for either overcoming persistent challenges or obstacles or opening entirely new fields for cancer research or clinical care. This Program Announcement complements the goals of the NCI's Innovative Molecular Analysis Technologies (IMAT) program by facilitating a path towards technology commercialization. Prior participation in the IMAT Program is not required for eligibility for this FOA. Applications are expected to indicate the significant attributes and advantages of the proposed technology over currently available technologies and conventional approaches. Click here to learn more.
Receipt Dates: May 28, 2014; November 4, 2014; May 27, 2015; November 4, 2015; May 27, 2016
October 1, 2013 - January 2014
A world-wide competition to bring emerging breast cancer technologies to market is being launched by the Avon Foundation for Women, in partnership with the National Cancer Institute (NCI), part of the NIH, and the Center for Advancing Innovation. The Avon Foundation will fund $250,000 in grants to launch the Breast Cancer Start-up Challenge aimed at teams of business, legal, medical/scientific, engineering, and computer science students, as well as seasoned entrepreneurs.
The challenge will begin on Oct. 1, 2013, in honor of Breast Cancer Awareness Month, with a call to universities to establish challenge teams. Teams accepted into the competition will have until January 2014 to submit a business plan for judging. Selected finalists will receive an award of $5,000 and will present a comprehensive business plan. Winning start-ups will be recognized in June 2014. It is anticipated that up to 30 successful start-ups will apply and be awarded funding from venture and other sources, which could range from $100,000 to over 1 million dollars.
Deadline: No deadline; applications accepted anytime
One-year grants to jump start new ideas in PD research. The Rapid Response Innovation Awards (RRIA) program supports high-risk, high-reward projects with little-to-no existing preliminary data, but with potential to significantly impact our understanding of Parkinson’s disease. Moreover, this program is well-suited for early exploratory studies that may open the field up to new targets or pathways that may ultimately feed the early drug development pipeline for a treatment of PD.
There is no deadline to apply; submit an Expressions of Interest here.
DELSIAis an independent nonprofit venture philanthropy affiliate of the autism research and advocacy foundation Autism Speaks. DELSIA provides funds to for-profit partners to advance the development of products that address unmet medical and behavioral health needs of the autism community. It was created as an innovative funding vehicle with the goal of improving outcomes for individuals with autism spectrum disorder (ASD). DELSIA aims to do this by ensuring that scientific breakthroughs and technological advances are developed into products that improve health and quality of life for individuals with autism and their families. Our purpose is to transform lives by serving as a catalyst to facilitate and accelerate the delivery and availability of impactful products.